<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-25T05:53:49Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/53866" metadataPrefix="edm">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/53866</identifier><datestamp>2025-02-20T12:41:52Z</datestamp><setSpec>com_10324_32522</setSpec><setSpec>com_10324_952</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_32523</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xsi:schemaLocation="http://www.w3.org/1999/02/22-rdf-syntax-ns# http://www.europeana.eu/schemas/edm/EDM.xsd">
<edm:ProvidedCHO rdf:about="https://uvadoc.uva.es/handle/10324/53866">
<dc:creator>Merino Antolín, Beatriz</dc:creator>
<dc:creator>Casanueva Álvarez, Elena</dc:creator>
<dc:creator>Quesada, Iván</dc:creator>
<dc:creator>González Casimiro, Carlos Manuel</dc:creator>
<dc:creator>Fernández Díaz, Cristina María</dc:creator>
<dc:creator>Postigo Casado, Tamara</dc:creator>
<dc:creator>Leissring, Malcolm A.</dc:creator>
<dc:creator>Kaestner, Klaus H.</dc:creator>
<dc:creator>Perdomo Hernández, Germán</dc:creator>
<dc:creator>Cózar Castellano, Irene</dc:creator>
<dc:date>2022</dc:date>
<dc:description>Producción Científica</dc:description>
<dc:description>Aims/hypothesis Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood. Insulin-degrading&#xd;
enzyme (IDE) is present within all islet cells, mostly in alpha cells, in both mice and humans. Furthermore, IDE can degrade&#xd;
glucagon as well as insulin, suggesting that IDE may play an important role in alpha cell function in vivo.&#xd;
Methods We have generated and characterised a novel mouse model with alpha cell-specific deletion of Ide, the A-IDE-KO&#xd;
mouse line. Glucose metabolism and glucagon secretion in vivo was characterised; isolated islets were tested for glucagon and&#xd;
insulin secretion; alpha cell mass, alpha cell proliferation and α-synuclein levels were determined in pancreas sections by&#xd;
immunostaining.&#xd;
Results Targeted deletion of Ide exclusively in alpha cells triggers hyperglucagonaemia and alpha cell hyperplasia, resulting in&#xd;
elevated constitutive glucagon secretion. The hyperglucagonaemia is attributable in part to dysregulation of glucagon secretion,&#xd;
specifically an impaired ability of IDE-deficient alpha cells to suppress glucagon release in the presence of high glucose or&#xd;
insulin. IDE deficiency also leads to α-synuclein aggregation in alpha cells, which may contribute to impaired glucagon secretion&#xd;
via cytoskeletal dysfunction. We showed further that IDE deficiency triggers impairments in cilia formation, inducing alpha cell&#xd;
hyperplasia and possibly also contributing to dysregulated glucagon secretion and hyperglucagonaemia.&#xd;
Conclusions/interpretation We propose that loss of IDE function in alpha cells contributes to hyperglucagonaemia in type 2&#xd;
diabetes</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://uvadoc.uva.es/handle/10324/53866</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>Springer</dc:publisher>
<dc:subject>32 Ciencias Médicas</dc:subject>
<dc:title>Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation</dc:title>
<dc:type>info:eu-repo/semantics/article</dc:type>
<edm:type>TEXT</edm:type>
</edm:ProvidedCHO>
<ore:Aggregation rdf:about="https://uvadoc.uva.es/handle/10324/53866#aggregation">
<edm:aggregatedCHO rdf:resource="https://uvadoc.uva.es/handle/10324/53866"/>
<edm:dataProvider>UVaDOC. Repositorio Documental de la Universidad de Valladolid</edm:dataProvider>
<edm:isShownAt rdf:resource="https://uvadoc.uva.es/handle/10324/53866"/>
<edm:isShownBy rdf:resource="https://uvadoc.uva.es/bitstream/10324/53866/1/Insulin-degrading-enzyme-ablation.pdf"/>
<edm:provider>Hispana</edm:provider>
<edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
</ore:Aggregation>
<edm:WebResource rdf:about="https://uvadoc.uva.es/bitstream/10324/53866/1/Insulin-degrading-enzyme-ablation.pdf">
<edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
</edm:WebResource>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>